Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$64.89 USD

64.89
4,647,904

-0.36 (-0.55%)

Updated Jun 11, 2024 04:00 PM ET

After-Market: $64.90 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Mark Vickery headshot

After-Hours Selling to Challenge Winning Streak Wednesday

Gilead, eBay and Rivian all beat on the bottom line in Q3, but all three are selling the news.

Gilead Sciences (GILD) Tops Q3 Earnings and Revenue Estimates

Gilead (GILD) delivered earnings and revenue surprises of 19.90% and 4.08%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Markets Await Consumer Credit Report

Markets Await Consumer Credit Report

Mark Vickery headshot

Can Markets Keep the Winning Streak Intact?

Uber missed on headline although business was good, D.R. Horton beat and raised, and the U.S. trade deficit got slimmer.

Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More

Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.

Earnings Preview: Illumina (ILMN) Q3 Earnings Expected to Decline

Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know

Gilead Sciences (GILD) closed at $77.88 in the latest trading session, marking a +1.64% move from the prior day.

Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 results.

Pfizer's (PFE) Key Drugs to Drive Q3 Earnings Amid COVID Decline?

Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.

Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales

Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.

USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day

USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day.

Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider

Gilead Sciences (GILD) concluded the recent trading session at $78.15, signifying a +0.76% move from its prior day's close.

Indrajit Bandyopadhyay headshot

3 Biotech Stocks With Decent Dividend for a Steady Return

Here we pick three medical device stocks, AbbVie (ABBV), Amgen (AMGN) and Gilead Sciences (GILD), which have a solid five-year dividend growth history.

Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know

Gilead Sciences (GILD) concluded the recent trading session at $77.56, signifying a -0.31% move from its prior day's close.

GILD or VRTX: Which Is the Better Value Stock Right Now?

GILD vs. VRTX: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights Walmart, NIKE, TJX, Gilead Sciences and Schlumberger

Walmart, NIKE, TJX, Gilead Sciences and Schlumberger are included in this Analyst Blog.

Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?

Smart Beta ETF report for VALQ

Sheraz Mian headshot

Q3 Earnings Scorecard and Analyst Reports for Walmart, Nike & TJX

Today's Research Daily features a real-time scorecard of the Q3 earnings season and new research reports on 16 stocks, including Walmart, Nike & TJX.

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

Gilead Sciences (GILD) reachead $79.20 at the closing of the latest trading day, reflecting a +2% change compared to its last close.

Nurix (NRIX) to Report Q3 Earnings: What's in Store?

On Nurix's (NRIX) Q3 earnings call, investors will likely focus on updates related to its pipeline candidates for hematologic malignancies and solid tumor indications.

Should You Invest in the VanEck Biotech ETF (BBH)?

Sector ETF report for BBH

Tango Therapeutics (TNGX) Rises 20% in a Month: Here's Why

The upside in Tango's (TNGX) shares can be attributed to the company's progress with its pipeline candidates. A recent acquisition offer for a biotech making similar drugs also bolstered this surge.

Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $75.06, denoting a +0.43% change from the preceding trading day.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $74.10, marking a -1.12% move from the previous day.